BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Week in Review: Kinex Pharmaceuticals Gains China Rights to Hanmi Pharmaceutical, Co., Ltd's Orascovery Program


7/15/2013 9:24:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

July 13, 2013 --Kinex Pharma of New York State extended its relationship with South Korea’s Hanmi Pharma by gaining the right to lead Hanmi’s Orascovery program development in China; Tianjin Weikai obtained exclusive China rights to manufacture and distribute TissueFlex®, a microbioreactor, from the UK’s Zyoxel; SciClone will collaborate with Soligenix of New Jersey to develop a personal medicine treatment for oral mucositis; Luqa Pharma partnered with BMG Pharma S.r.l. of Italy to bring BMG’s dermatology and oral care products to China; DelMar Pharma reported that its partner, Guangxi Wuzhou Pharma, received government support for its collaboration with DelMar; GlaxoSmithKline’s China scandals have cast a pall over the entire company’s reputation, and its problems may affect the China operations of other multinationals as well; GSK executives in China have reportedly confessed to bribing government officials, hospitals and doctors, a scheme that has been in place for “years;” GSK’s sales force in Chengdu alledgedly hatched a scheme to pay doctors to prescribe Botox, the wrinkle treatment, offering payments up to $490; and the China arm of a global trial caused a nine-month delay in the approval process of Eliquis because of errors in trial administration. More details….

Stock Symbols: (NSDQ: SCLN) (OTCQB: SNGX) (OTCQB: DMPI) (SHA: 600252) (NYSE: GSK)

Help employers find you! Check out all the jobs and post your resume.


Read at ChinaBio Today

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES